pharma · Acute Coronary Syndrome
Xiangya Hospital of
Second Xiangya Hospital of Central South University
Second Xiangya Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Coronary Syndrome. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)
Changsha, CN HQ
1906 Founded
316 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Changsha, CN
- Founded
- 1906
- Employees
- 316
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Rivaroxaban 2.5 mg
Approved · small molecule · Acute Coronary Syndrome
Rivaroxaban 2.5 mg for Acute Coronary Syndrome is a Approved program (small_molecule) at Second Xiangya Hospital of Central South University with 1 ClinicalTrials.gov record(s).
Internal code H-REPLACE-201711
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Second Xiangya Hospital of Central South University
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Acute Coronary Syndrome
- Status
- completed
- Trials
- 1